FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:116-118 July 14, 2005 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Advisory committees to the Food and Drug Administration (FDA) help the agency make decisions about the approval of medications and medical devices, among other issues. Membership on these committees is subject to detailed policies and procedures for managing potential conflicts of interest and for balancing possible conflicts against the agency's need for advisers with relevant scientific expertise (see box).^1,2 Two recent high-profile meetings have raised questions about the agency's approach and whether it should change.

View this table: [in this window] [in a new window]   Managing Conflicts of Interest for FDA Advisory Panels.

 
In February, the FDA convened a joint meeting of the Arthritis Advisory Committee and the Drug . . . [Full Text of this Article]

Source Information

Dr. Steinbrook is a national correspondent for the Journal.

This article has been cited by other articles:

• Lurie, P., Almeida, C. M., Stine, N., Stine, A. R., Wolfe, S. M. (2006). Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings.. JAMA 295: 1921-1928 [Abstract] [Full Text]  
• Ray, W. A., Stein, C. M. (2006). Reform of Drug Regulation -- Beyond an Independent Drug-Safety Board. NEJM 354: 194-201 [Full Text]